6coy: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
The entry | ==Human CLC-1 chloride ion channel, transmembrane domain== | ||
<StructureSection load='6coy' size='340' side='right' caption='[[6coy]], [[Resolution|resolution]] 3.36Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6coy]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6COY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6COY FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6coz|6coz]]</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6coy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6coy OCA], [http://pdbe.org/6coy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6coy RCSB], [http://www.ebi.ac.uk/pdbsum/6coy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6coy ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[[http://www.uniprot.org/uniprot/CLCN1_HUMAN CLCN1_HUMAN]] Thomsen and Becker disease. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/CLCN1_HUMAN CLCN1_HUMAN]] Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.<ref>PMID:12456816</ref> <ref>PMID:22521272</ref> <ref>PMID:26007199</ref> <ref>PMID:26502825</ref> <ref>PMID:26510092</ref> <ref>PMID:7951242</ref> <ref>PMID:8112288</ref> <ref>PMID:9122265</ref> <ref>PMID:9736777</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
CLC channels mediate passive Cl(-) conduction, while CLC transporters mediate active Cl(-) transport coupled to H(+) transport in the opposite direction. The distinction between CLC-0/1/2 channels and CLC transporters seems undetectable by amino acid sequence. To understand why they are different functionally we determined the structure of the human CLC-1 channel. Its 'glutamate gate' residue, known to mediate proton transfer in CLC transporters, adopts a location in the structure that appears to preclude it from its transport function. Furthermore, smaller side chains produce a wider pore near the intracellular surface, potentially reducing a kinetic barrier for Cl(-) conduction. When the corresponding residues are mutated in a transporter, it is converted to a channel. Finally, Cl(-) at key sites in the pore appear to interact with reduced affinity compared to transporters. Thus, subtle differences in glutamate gate conformation, internal pore diameter and Cl(-) affinity distinguish CLC channels and transporters. | |||
Structure of the CLC-1 chloride channel from Homo sapiens.,Park E, MacKinnon R Elife. 2018 May 29;7. pii: 36629. doi: 10.7554/eLife.36629. PMID:29809153<ref>PMID:29809153</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6coy" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: MacKinnon, R]] | |||
[[Category: Park, E]] | |||
[[Category: Channel]] | |||
[[Category: Chloride]] | |||
[[Category: Clc]] | |||
[[Category: Transport protein]] | |||
Revision as of 07:38, 14 June 2018
Human CLC-1 chloride ion channel, transmembrane domain
| ||||||||||||